Crizotinib

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H22Cl2FN5O
Molecular Weight	450.337
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Crizotinib

Structure Search

SMILES

C[C@@H](OC1=CC(=CN=C1N)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C=CC(F)=C4Cl

InChI

InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N

InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H22Cl2FN5O
Molecular Weight	450.337
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:39:59 UTC 2023` Edited by `admin` on `Sat Dec 16 17:39:59 UTC 2023`
Record UNII	53AH36668S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Crizotinib

Official Name

English

CRIZOTINIB [USAN]

Common Name

English

CRIZOTINIB [JAN]

Common Name

English

CRIZOTINIB [ORANGE BOOK]

Common Name

English

CRIZOTINIB [MI]

Common Name

English

3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

Systematic Name

English

PF-02341066

Code

English

2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-

Systematic Name

English

NSC-756645

Code

English

CRIZOTINIB [MART.]

Common Name

English

CRIZOTINIB [VANDF]

Common Name

English

1066

Code

English

PF-2341066

Common Name

English

Crizotinib [WHO-DD]

Common Name

English

XALKORI

Brand Name

English

crizotinib [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QL01XE16

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

FDA ORPHAN DRUG

379812

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

WHO-ATC

L01XE16

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

FDA ORPHAN DRUG

834721

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

FDA ORPHAN DRUG

310610

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

NDF-RT

N0000175605

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

FDA ORPHAN DRUG

379712

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

NCI_THESAURUS

C141136

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

LIVERTOX

NBK548638

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

NCI_THESAURUS

C129825

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

Code System Code Type Description

MERCK INDEX

m3847

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Merck Index

DRUG BANK

DB08865

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

ChEMBL

CHEMBL601719

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

DAILYMED

53AH36668S

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

NDF-RT

N0000182139

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Cytochrome P450 2B6 Inhibitors [MoA]

IUPHAR

4903

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

CAS

877399-52-5

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

USAN

WW-148

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

CHEBI

64310

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

NDF-RT

N0000185503

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

P-Glycoprotein Inhibitors [MoA]

LACTMED

Crizotinib

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

EVMPD

SUB32267

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

NDF-RT

N0000190114

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Cytochrome P450 3A Inhibitors [MoA]

JAPANESE REVIEW

XALKORI

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

APPROVED MARCH 2012

INN

9301

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

NDF-RT

N0000191265

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Organic Cation Transporter 1 Inhibitors [MoA]

NDF-RT

N0000187061

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Organic Cation Transporter 2 Inhibitors [MoA]

NCI_THESAURUS

C74061

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

MESH

C551994

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

SMS_ID

100000124345

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

NSC

756645

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

NDF-RT

N0000020000

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Receptor Tyrosine Kinase Inhibitors [MoA]

PUBCHEM

11626560

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

EPA CompTox

DTXSID701009329

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

RXCUI

1148495

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

RxNorm

DRUG CENTRAL

4187

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

FDA UNII

53AH36668S

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

WIKIPEDIA

CRIZOTINIB

Created by admin on Sat Dec 16 17:40:00 UTC 2023 , Edited by admin on Sat Dec 16 17:40:00 UTC 2023

PRIMARY

Related Record Type Details


					53AH36668S

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					53AH36668S

EXCRETED UNCHANGED

Qualification:

FECAL

Amount:


					Z63P44CE4Z

Crizotinib hydrochloride

SALT/SOLVATE -> PARENT

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Comments:

Crizotinib is a substrate for P-glycoprotein in vitro.


					FB99MH8KWZ

Crizotinib acetate

SALT/SOLVATE -> PARENT

Amount:


					AIN96D6SGL

OATP1B1

TRANSPORTER -> SUBSTRATE


					QA085PMU8Q

HEPATOCYTE GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Comments:

In vitro studies in human liver microsomes demonstrated that crizotinib is a time-dependent inhibitor of CYP3A.

Interaction Type:

INHIBITOR

Qualification:

IC50

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

Binding of crizotinib to human plasma proteins in vitro is 91% and is independent of drug concentration.

Amount:


					4M56WLI1MN

ANAPLASTIC LYMPHOMA KINASE

TARGET -> INHIBITOR

Interaction Type:

INHIBITOR

Qualification:

IC50

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR

Amount:


					8EJE45ZR0I

TYROSINE-PROTEIN KINASE RECEPTOR UFO

TARGET -> INHIBITOR

Related Record Type Details


					CP57HGS9U5

METABOLITE LESS ACTIVE -> PARENT

Amount:

Related Record Type Details


					53AH36668S

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
ORAL BIOAVAILABILITY	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC				DOSE INTRAVENOUS ADMINISTRATION

Biological Half-life	PHARMACOKINETIC				SINGLE-DOSE ADMINISTRATION

Tmax	PHARMACOKINETIC				ORAL SINGLE-DOSE ADMINISTRATION

CSF/PLASMA RATIO	PHARMACOKINETIC				COMMENT PHARMACOKINETIC